HLB’s Rivoceranib anti-cancer drug recently received approval in China as a treatment for ovarian cancer, paving the way for the company to expand the drug's uses in the global market, the company said Monday. 

The company added that the expansion of Rivoceranib from gastric and liver to ovarian cancers means that global pharmaceutical companies are likely to be interested in using the drug for combination therapy. 

Please refer to the following website for further details :HLB's Rivoceranib earns approval in China for ovarian cancer treatment